Search

Your search keyword '"Glueck, Reinhard"' showing total 34 results
Start Over Author "Glueck, Reinhard" Search Limiters Peer Reviewed Publication Year Range Last 50 years
34 results on '"Glueck, Reinhard"'

19. Pre-clinical antigenicity studies of an innovative multivalent vaccine for human visceral leishmaniasis.

Author

Cecílio, Pedro, Pérez-Cabezas, Begoña, Fernández, Laura, Moreno, Javier, Carrillo, Eugenia, Requena, José M., Fichera, Epifanio, Reed, Steven G., Coler, Rhea N., Kamhawi, Shaden, Oliveira, Fabiano, Valenzuela, Jesus G., Gradoni, Luigi, Glueck, Reinhard, Gupta, Gaurav, and Cordeiro-da-Silva, Anabela

Subjects
VISCERAL leishmaniasis, EPITOPES, MEDICATION safety, IMMUNOGENETICS, DRUG side effects, RECOMBINANT proteins, VACCINATION
Abstract

The notion that previous infection by Leishmania spp. in endemic areas leads to robust anti-Leishmania immunity, supports vaccination as a potentially effective approach to prevent disease development. Nevertheless, to date there is no vaccine available for human leishmaniasis. We optimized and assessed in vivo the safety and immunogenicity of an innovative vaccine candidate against human visceral leishmaniasis (VL), consisting of Virus-Like Particles (VLP) loaded with three different recombinant proteins (LJL143 from Lutzomyia longipalpis saliva as the vector-derived (VD) component, and KMP11 and LeishF3+, as parasite-derived (PD) antigens) and adjuvanted with GLA-SE, a TLR4 agonist. No apparent adverse reactions were observed during the experimental time-frame, which together with the normal hematological parameters detected seems to point to the safety of the formulation. Furthermore, measurements of antigen-specific cellular and humoral responses, generally higher in immunized versus control groups, confirmed the immunogenicity of the vaccine formulation. Interestingly, the immune responses against the VD protein were reproducibly more robust than those elicited against leishmanial antigens, and were apparently not caused by immunodominance of the VD antigen. Remarkably, priming with the VD protein alone and boosting with the complete vaccine candidate contributed towards an increase of the immune responses to the PD antigens, assessed in the form of increased ex vivo CD4+ and CD8+ T cell proliferation against both the PD antigens and total Leishmania antigen (TLA). Overall, our immunogenicity data indicate that this innovative vaccine formulation represents a promising anti-Leishmania vaccine whose efficacy deserves to be tested in the context of the “natural infection”. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

20. Immunogenicity and safety of a novel MMR vaccine (live, freeze-dried) containing the Edmonston-Zagreb measles strain, the Hoshino mumps strain, and the RA 27/3 rubella strain: Results of a randomized, comparative, active controlled phase III clinical trial

Author

Sood, Ashwani, Mitra, Monjori, Joshi, Himanshu Arvind, Nayak, Uma Siddhartha, Siddaiah, Prashanth, Babu, T. Ramesh, Mahapatro, Samarendra, Sanmukhani, Jayesh, Gupta, Gaurav, Mittal, Ravindra, and Glueck, Reinhard

Published
2017
Full Text
View/download PDF

22. Protective Efficacy in a Hamster Model of a Multivalent Vaccine for Human Visceral Leishmaniasis (MuLeVaClin) Consisting of the KMP11, LEISH-F3+, and LJL143 Antigens in Virosomes, Plus GLA-SE Adjuvant.

Author

Fernández, Laura, Solana, Jose Carlos, Sánchez, Carmen, Jiménez, Mª Ángeles, Requena, Jose M., Coler, Rhea, Reed, Steven G., Valenzuela, Jesus G., Kamhawi, Shaden, Oliveira, Fabiano, Fichera, Epifanio, Glueck, Reinhard, Bottazzi, Maria Elena, Gupta, Gaurav, Cecilio, Pedro, Pérez-Cabezas, Begoña, Cordeiro-da-Silva, Anabela, Gradoni, Luigi, Carrillo, Eugenia, and Moreno, Javier

Subjects
VISCERAL leishmaniasis, SALIVARY proteins, HAMSTERS, HUMORAL immunity, CHIMERIC proteins, IMMUNOGLOBULINS
Abstract

Visceral leishmaniasis (VL) is the most severe clinical form of leishmaniasis, fatal if untreated. Vaccination is the most cost-effective approach to disease control; however, to date, no vaccines against human VL have been made available. This work examines the efficacy of a novel vaccine consisting of the Leishmania membrane protein KMP11, LEISH-F3+ (a recombinant fusion protein, composed of epitopes of the parasite proteins nucleoside hydrolase, sterol-24-c-methyltransferase, and cysteine protease B), and the sand fly salivary protein LJL143, in two dose ratios. The inclusion of the TLR4 agonist GLA-SE as an adjuvant, and the use of virosomes (VS) as a delivery system, are also examined. In a hamster model of VL, the vaccine elicited antigen-specific immune responses prior to infection with Leishmania infantum. Of note, the responses were greater when higher doses of KMP11 and LEISH-F3+ proteins were administered along with the GLA-SE adjuvant and/or when delivered within VS. Remarkably, hamsters immunized with the complete combination (i.e., all antigens in VS + GLA-SE) showed significantly lower parasite burdens in the spleen compared to those in control animals. This protection was underpinned by a more intense, specific humoral response against the KMP11, LEISH-F3+, and LJL143 antigens in vaccinated animals, but a significantly less intense antibody response to the pool of soluble Leishmania antigens (SLA). Overall, these results indicate that this innovative vaccine formulation confers protection against L. infantum infection, supporting the advancement of the vaccine formulation into process development and manufacturing and the conduction of toxicity studies towards future phase I human clinical trials. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

34. Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma

Author

Cantarella, Giuseppina, Liniger, Matthias, Zuniga, Armando, Schiller, John T., Billeter, Martin, Naim, Hussein Y., and Glueck, Reinhard

Subjects
*RECOMBINANT viruses, *MEASLES virus, *HUMAN papillomavirus vaccines, *CANCER prevention, *CERVICAL cancer, *PLASMIDS, *GENE expression, *VIRAL genetics
Abstract

Abstract: Cervical cancer is mainly associated with HPV genotype 16 infection. Recombinant measles virus (rMV) expressing HPV genotype 16 L1 capsid protein was generated by construction of an antigenomic plasmid, followed by rescue using the human “helper” cell line 293-3-46. In cell cultures the recombinant MV-L1 virus replicated practically as efficiently as the standard attenuated MV established as commercial vaccine, devoid of the transgene. The high genetic stability of MVb2-L1 was confirmed by 10 serial viral transfers in cell culture. In transgenic mice expressing the MV receptor CD46 the recombinant induced strong humoral immune responses against both MV and HPV; the antibodies against L1 exhibited mainly neutralizing capacity. Our data suggest that MV is a promising vehicle for development of inexpensive and efficient vaccines protecting from HPV infection. [Copyright &y& Elsevier]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results